Eliem Therapeutics Inc

NASDAQ ELYM

Download Data

Eliem Therapeutics Inc Accounts Receivable Turnover Ratio 3 year CAGR for the quarter ending March 31, 2024

Eliem Therapeutics Inc Accounts Receivable Turnover Ratio 3 year CAGR is NA for the quarter ending March 31, 2024. The accounts receivable turnover ratio measures the efficiency of a company in collecting payments from its customers. It is calculated by dividing the company's revenue by its accounts receivable. This ratio provides insight into how quickly a company collects outstanding funds owed to it. A higher turnover ratio implies that the company efficiently converts credit sales into cash, while a lower ratio may indicate delays in collecting payments or potential issues with credit management. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Eliem Therapeutics Inc Accounts Receivable Turnover Ratio for the quarter ending March 31, 2023 was 0.00, a 0.00% change year over year.
  • Eliem Therapeutics Inc Accounts Receivable Turnover Ratio for the quarter ending March 31, 2022 was 0.00, a 0.00% change year over year.
  • Eliem Therapeutics Inc Accounts Receivable Turnover Ratio for the quarter ending March 31, 2021 was 0.00.
NASDAQ: ELYM

Eliem Therapeutics Inc

CEO Mr. Robert W. Azelby M.B.A.
IPO Date Aug. 10, 2021
Location United States
Headquarters 23515 NE Novelty Hill Road, Redmond, WA, United States, 98053
Employees 9
Sector Healthcare
Industry Biotechnology
Description

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Similar companies

MNOV

MediciNova Inc

NA

NA

ANEB

Anebulo Pharmaceuticals Inc

NA

NA

HCWB

HCW Biologics Inc

NA

NA

AVTE

Aerovate Therapeutics Inc

NA

NA

ADAG

Adagene Inc

NA

NA

ACRV

Acrivon Therapeutics Inc. Common Stock

NA

NA

ANTX

AN2 Therapeutics Inc

NA

NA

CYT

Cyteir Therapeutics Inc

NA

NA

IPSC

Century Therapeutics Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email